tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Medacta Group SA Reports Strong H1 2025 Revenue Growth and Upgrades Guidance

Story Highlights
  • Medacta achieved a 19.8% revenue growth in H1 2025, reaching Euro 344.1 million.
  • The company upgraded its full-year and mid-term guidance, reflecting strong market positioning.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Medacta Group SA Reports Strong H1 2025 Revenue Growth and Upgrades Guidance

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Medacta Group SA ( (CH:MOVE) ) has issued an announcement.

Medacta Group SA reported a significant revenue growth of 19.8% in constant currency for the first half of 2025, reaching Euro 344.1 million. This growth was driven by substantial performance across all business lines and geographic markets, with notable increases in the Asia Pacific and North America regions. The company also upgraded its full-year and mid-term guidance, reflecting its strong market position and successful integration of Parcus Medical, which contributed to the revenue increase. Medacta’s focus on innovative solutions and medical education continues to bolster its industry standing and offers promising implications for stakeholders.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF160.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.

More about Medacta Group SA

Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 70 countries.

Average Trading Volume: 8,461

Technical Sentiment Signal: Buy

Current Market Cap: CHF2.8B

For a thorough assessment of MOVE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1